A Study of miRNA 371 in Patients With Germ Cell Tumors (NCT04435756)

🧪 Interventions in This Study

• Biomarker Analysis (OTHER)
• Blood Product Collection (PROCEDURE)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patients must have a new diagnosis of a germ cell tumor. confirmed pathologically or serologically (diagnostic elevation of human chorionic gonadotropin \[HCG\]/alpha-fetoprotein \[AFP\]). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible
2. If surgery is planned, male patients with clinical stage I testicular cancer must have orchiectomy completed within 42 days prior to registration
3. Patients must be registered within 42 days after diagnosis and prior to initiation of a management plan or treatment for the disease
4. Patients must have initial imaging, laboratory and other clinical evaluations (see below) performed within 42 days prior to registration. Imaging reports, pathology reports and performance status will be collected
5. Patients must have beta-human chorionic gonadotropin (beta- HCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration
6. NOTE: If the patient had an orchiectomy prior to registration, report tumor marker values before and after surgery on the Baseline Tumor Marker form
7. Patients must have risk of relapse assessment determined by the local investigator prior to registration
8. Patients must agree to submit required specimens for defined translational medicine studies. These specimens are drawn at the same time as standard laboratory evaluations (beta-HCG, AFP, and LDH); NOTE: Ideally, patients should be willing to return to their center performing surveillance (registering site) for the duration of the study to ensure that specimens are timed to standard clinical observations (the registering site's surveillance schedule)
9. Patients must be offered participation in specimen banking for future research. With patient's consent, specimens must be submitted.
10. Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
11. As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (424 Sites)

Showing the first 25 of 424 sites.

• Banner MD Anderson Cancer Center — Gilbert, Arizona
• Kingman Regional Medical Center — Kingman, Arizona
• University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• Mercy Hospital Fort Smith — Fort Smith, Arkansas
• Kaiser Permanente-Anaheim — Anaheim, California
• Kaiser Permanente-Deer Valley Medical Center — Antioch, California
• PCR Oncology — Arroyo Grande, California
• Kaiser Permanente-Baldwin Park — Baldwin Park, California
• Kaiser Permanente-Bellflower — Bellflower, California
• Keck Medicine of USC Buena Park — Buena Park, California
• Epic Care-Dublin — Dublin, California
• Kaiser Permanente Dublin — Dublin, California
• Bay Area Breast Surgeons Inc — Emeryville, California
• Epic Care Partners in Cancer Care — Emeryville, California
• Kaiser Permanente-Fontana — Fontana, California
• Kaiser Permanente-Fremont — Fremont, California
• Fresno Cancer Center — Fresno, California
• Kaiser Permanente-Fresno — Fresno, California
• Kaiser Permanente - Harbor City — Harbor City, California
• Keck Medicine of USC Huntington Beach — Huntington Beach, California
• Kaiser Permanente-Irvine — Irvine, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Loma Linda University Medical Center — Loma Linda, California

📞 Contact the Study Coordinator

Phone: (877) 632-6789

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Germ Cell Tumor

• Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors — Boston, Massachusetts
• Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours — New York, New York
• A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy — Charlotte, North Carolina
• Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors — Basking Ridge, New Jersey
• Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT — Indianapolis, Indiana

Explore by condition: All Germ Cell Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.